CompletedNot Applicable

Inflammation, Epigenetics in CHF Patients With AF

Italy164 participantsStarted 2020-01-01

Plain-language summary

the goal of this case-control cross-sectional study is assessing in a cohort of patients with CHF and permanent AF * The serum levels of some candidate cytokine variables and their relationship with some selected metabolic variables and some echocardiographic variables. * the expression degree of some selected miRNA with a pathogenetic relation to atrial fibrillation and the related cardiac remodelling. * to analyze the correlation between selected miRNA and the selected cytokines.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria * ≥18 years * Left ventricular ejection fraction \>40% * New York Heart Association class II-IV symptoms * NT-proBNP ≥600 pg/mL, or ≥900 pg/mL if AF was present on baseline electrocardiography Exclusion Criteria \- Other AF subtypes (paroxysmal, persistent, long-standing persistent) At least one of the following criteria: * Acute heart failure * NYHA IV * NT-proBNP \>4000 pg/mL * Significant valvular disease * Mechanical prosthesis * Cardiovascular implantable devices * Active malignancy * Inflammatory or infectious diseases * Severe renal (eGFR \<30 mL/min/m²) or hepatic failure * Chronic steroid/anti-inflammatory therapy

What they're measuring

inflammation and structural cardiac remodelling

Timeframe: From January 2020 to May 2022

Trial details

NCT IDNCT07152301

SponsorUniversity of Palermo

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-05-31

View on ClinicalTrials.gov More Congestive Heart Failure Chronic trials